Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma
Axel Hauschild, Sanjiv S. Agarwala, Uwe Trefzer, David Hogg, Caroline Robert, Peter Hersey, Alexander Eggermont, Stephan Grabbe, Rene Gonzalez, Jens Gille, Christian Peschel, Dirk Schadendorf, Claus Garbe, Steven O'Day, Adil Daud, J. Michael White, Chenghua Xia, Kiran Patel, John M. Kirkwood, Ulrich Keilholz
Research output: Contribution to journal › Article › peer-review
489Citations
(Scopus)
Fingerprint
Dive into the research topics of 'Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma'. Together they form a unique fingerprint.